BioNTech Announces Its Third Quarter 2021 Profit

Developing one of the first vaccines against the coronavirus, the Pfizer-BioNTech duo managed to become one of the most valued companies in a short time thanks to their vaccines. from these companies BioNTech, shared its financial results for the third quarter of 2021 today. Although BioNTech generated less revenue compared to the previous quarter, it experienced an increase in profit.

According to the announced data, BioNTech made a total of 6 billion 87 million euro revenue achieved. This value was at the level of 67.5 million euros in the same period of last year. The portion of the company’s income that enters the cash register as profit 3 billion 211 million euros it happened. This value was not at the profit level but at the loss level in the same period of the previous year. BioNTech announced a loss of 210 million euros in the third quarter of 2020.

A total profit of 7 billion 126 million euros was made in the 9 months of 2021:

With the announcement of the data for the third quarter of this year, the total revenue generated by BioNTech in January-September 2021 is approximately 13 billion 444 million reached. In the first 9 months of 2020, this number was 136.9 million euros. The total profit of the company from its revenue until September 7 billion 126 million euros reached. In the same period of last year, a loss of $ 351.7 million was announced.

In addition to these data, BioNTech overestimated the analysts’ estimates, predicting the total revenue it will generate this year. up to 17 billion euros announced that it could rise. Finally, by the end of 2021, the company this year 3 billion doses of vaccine production He stated that they plan to have done this and that they expect to increase this number to 4 billion dollars in 2022.